6
Oct
2026

USV Private Limited

Exhibitor at CPHI Milan 2026 stand 18G49, Finished Dosage & Formulation
About Us

USV is a 60 year old company based out of Mumbai with close to US$ 500 Million revenues mostly from the Diabetic and Cardiac segment. We are among the top 15 companies in India with presence in over 60+ countries with 100+ satisfied customers with our exports close to around US$ 100 Million. With over 100+ product approvals worldwide and 30+ DMF filed across the globe, we offer value added products in the Oral Solids, Injectables (PFS, Vials), Opthalmics, Biosimilars (Pegfilgrastim) and Peptides.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    India
  • On CPHI since:
    2015
  • Certificates:
    4
  • Employees:
    5000+
Company types
Distributor/Import Export
Manufacturer/Innovator
Pharmaceutical company
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 18G49, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • Anti Histaminic

    Product Anti Histaminic

    Usv Ltd provides wide range of opthalmic products which includes anti histaminic. Contact us for more information.
  • Sevelamer Carbonate

    Product Sevelamer Carbonate

    Usv Ltd provides wide range of api products which includes sevelamer carbonate. Contact us for more information.
  • Atovaquone USP (Form – I and III)

    Product Atovaquone USP (Form – I and III)

    Usv Ltd provides wide range of api products which includes atovaquone usp (form – i and iii). Contact us for more information.
  • Sevelamer HCl

    Product Sevelamer HCl

    Usv Ltd provides wide range of api products which includes sevelamer hcl. Contact us for more information.
  • Bazedoxifene Acetate

    Product Bazedoxifene Acetate

    Usv Ltd provides wide range of api products which includes bazedoxifene acetate. Contact us for more information.